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Blood rheology is impaired in hypertensive patients. The alteration involves blood and plasma viscosity, and
the erythrocyte behaviour is often abnormal. The hemorheological pattern appears to be related to some
pathophysiological mechanisms of hypertension and to organ damage, in particular left ventricular hyper-
trophy and myocardial ischemia. Abnormalities have been observed in erythrocyte membrane fluidity,
explored by fluorescence spectroscopy and electron spin resonance. This may be relevant for red cell flow
in microvessels and oxygen delivery to tissues. Although blood viscosity is not a direct target of anti-
hypertensive therapy, the rheological properties of blood play a role in the pathophysiology of arterial
hypertension and its vascular complications.
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Introduction
The relationship between arterial hypertension and
blood rheology has been investigated for a long time.
Despite the bulk of experimental and clinical results accu-
mulated during the last decades, some relevant questions
are still open. This paper will review the hemorheological
alterations described in hypertensive subjects and their
possible link with pathophysiological mechanisms and
organ damage. The influence of antihypertensive drugs on
the rheological pattern will be briefly discussed, and the
results obtained by the authors investigating erythrocyte
and leukocyte microrheology will be described. 
Arterial blood hypertension can be either ‘essential’ or
‘secondary’. In the first one, also called ‘idiopathic’ and
much more common than the other, there is not an under-
lying disease causing the rise in blood pressure, which
happens in secondary hypertension. The studies described
in this paper regard essential hypertension unless it is dif-
ferently stated.
The hyperviscosity syndrome in arterial hyper-
tension
Applying the Poiseuille’s law to blood circulation it is
clear that an elevated blood pressure within arteries can be
the result of either an increase of cardiac output or an
increase of vascular resistance. The latter can be due not
only to an abnormal state of vasoconstriction but also to
higher blood viscosity. 
The pathophysiology of essential hypertension is not
definitely clarified. Several complex mechanisms are
involved in the regulation of cardiac output, blood volume
and composition, vascular tone. Regulatory mechanisms
involve renal function, autonomic nervous system and
hormones like the renin-angiotensin-aldosterone axis. A
main role in the regulation of vascular tone is played by
endothelium, which is the cellular layer covering the inter-
nal surface of blood vessels, and is able to modulate the
underlying smooth muscle cell contractility. A dysfunction
of any of these regulatory mechanisms can alter the blood
pressure level (Giles et al., 2012). 
The rheological properties of blood can interact with
many pathophysiological aspects of arterial hypertension.
Despite the direct role of blood rheology as a determinant
of vascular resistence, the early studies paid much more
attention to the vascular component of resistance than to
the blood viscosity. Some pioneering observations date
back to the early decades of the 20th century, and the paper
by Harris and McLoughlin, published in 1930 (Harris and
McLoughlin, 1930), is often considered the first, single
example of interest in the topic. Only in the 1970s and
1980s a great deal of research was addressed to the blood
rheology pattern in hypertensive subjects. In 1990
Chabanel and Chien (Chabanel and Chien, 1990) exhaus-
tively reviewed the results accumulated until then, describ-
ing the hyperviscosity syndrome associated with essential
hypertension. Untreated patients commonly showed an
increase in blood viscosity, hematocrit, plasma viscosity,
fibrinogen and erythrocyte aggregability, and a decrease in
erythrocyte deformability. Blood hyperviscosity had been
detected over a wide range of shear rates and mostly
explained by an increase of both hematocrit and plasma
viscosity. The latter was due to a high level of fibrinogen
and secondarily to an increase in other high molecular
weight plasma proteins, while high hematocrit was at least
partly caused by a plasma volume contraction. As regards
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erythrocyte deformability, in these early studies it was
determined by viscometry or filtration techniques.
The altered rheological pattern accompanying essential
hypertension belongs to the ‘secondary’ hyperviscosity
syndromes, according to the classification by Di Perri and
Forconi (Di Perri et al., 1983; Forconi et al., 1987). The
‘primary’ hyperviscosity syndromes are those in which a
marked primary alteration of a blood component (circu-
lating cell number, erythrocyte deformability or plasma
viscosity) causes an increase in blood viscosity, often
directly responsible for symptoms. This mainly happens in
hematological diseases and the correction of blood vis-
cosity through apheretic techniques is a useful therapeutic
measure. The secondary hyperviscosity syndromes are
associated to common diseases including arterial hyper-
tension, diabetes mellitus, vascular atherosclerotic dis-
eases, which share the trend towards ischemia, that is an
insufficient blood supply to tissues. In the secondary syn-
dromes hyperviscosity is usually not as great as in the pri-
mary ones and is not a primary therapeutic target. The
relationship between hyperviscosity and ischemia is not
clear, as it is part of a complex interplay between blood
and vascular wall components.
Blood rheology and the pathophysiology of
hypertension
In the studies surveyed by Chabanel and Chien, the
rheological alterations of hypertensive patients showed
some variability, the less constant finding being the
increase in hematocrit. Here we face a basic problem
inherent in this research field. Even excluding secondary
hypertension, hypertensive patients are not a homoge-
neous population as regards pathophysiological mecha-
nisms, such as salt sensitivity, renin-angiotensin system or
autonomic balance. So it is not surprising that, since the
early phase of research about hypertension and blood rhe-
ology, attention was focused on the possible link between
some pathophysiological aspects of hypertension and
hemorheology.
In the paper by Chien (Chien, 1986), patients were strat-
ified according to the daily renal sodium excretion, which
showed a strong, inverse relationship with the plasma
activity of renin, a pressure-regulating factor produced by
kidneys. Both the hypertensives and the borderline sub-
jects with the highest renin levels had the highest levels of
blood viscosity, hematocrit and plasma viscosity. Mea-
surements of plasma proteins indicated an increased level
of globulin and fibrinogen in hypertensives. Recent
research has provided some new insights into this aspect.
Angiotensin II, a component of the regulatory pathway
initiated by renin, acts directly as a growth factor through
the AT1 receptor, stimulating proliferation of erythroid
progenitors in bone marrow and, additionally, it enhances
erythropoietin secretion (Vlahakos et al., 2010). This
mechanism also explains anaemia that has been described
as a side effect of drugs interfering with the renin-angio-
tensin system (Sica and Mannino, 2007).
Another aspect which is deemed central in the patho-
physiology of hypertension is the autonomic imbalance,
consisting in a sympathetic overactivity. As Brook and
Julius outlined it in 2000 (Brook and Julius, 2000), the
sympathetic overdrive may be responsible for metabolic,
trophic, hemodynamic and thrombotic consequences; the
overal picture largely overlaps what we call metabolic
syndrome. In fact it encompasses aspects like cell resis-
tance to insulin action, hyperinsulinemia and obesity,
interrelating in a complex way. Among the consequences
of sympathetic hyperactivity there is high hematocrit, in
the context of a prothrombotic pattern. An increase in
hematocrit may not be the only link between sympathetic
hyperactivity and thrombotic risk. In 1984 Caimi et al.
(Caimi et al., 1984) subdivided a group of hypertensives
according to the plasma level of the sympathetic mediator
norepinephrine. There was no difference in blood and
plasma viscosity between the two subgroups, neither was
there any difference in hematocrit, despite what could be
expected, but the high-norepinephrine subgroup had a
higher fibrinogen level.
Whatever relation there is between haemorheological
abnormalities and the pathophysiological mechanisms of
hypertension, it is still uncertain whether blood rheology
actually contributes to the onset and maintenance of hyper-
tension or not. The study of the secondary forms of arterial
hypertension could be useful because in them the mech-
anisms leading to the raising of blood pressure are more
definite. Unfortunately, only a few studies have focused on
blood rheology in human cases of secondary arterial hyper-
tension. The studies on different animal models of arterial
hypertension have suggested that the hemorheological
alterations are not a mere non-specific consequence of high
blood pressure (Hacioglu et al., 2002).
A human disease in which a relevant amount of data
have been obtained is pre-eclampsia, a condition that com-
plicates the second half of pregnancy and is characterized
by arterial hypertension and protein loss through urine. It
has been suggested that an altered blood rheology could
impair circulation in the placenta vessels, leading to
impaired fetal growth and increased risk of perinatal com-
plications. Hemorheological abnormalities such as hyper-
viscosity and high fibrinogen level during the first
trimester of pregnancy have been put forward as markers
for the development of pregnancy-induced hypertension
(Robins et al., 2005). However, the relationship between
blood rheology and complicated pregnancy is not clear. In
the largest study available on this issue (von Tempelhoff et
al., 2009) pregnant women with pre-eclampsia showed a
significantly increased erythrocyte aggregation in com-
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parison with normal pregnant women, while plasma vis-
cosity was not significantly altered. As regards the fetal
outcome, higher maternal hematocrit and plasma viscosity
were related to better results in tests evaluating the new-
born’s physical condition.
Blood rheology and organ damage in hyperten-
sion
Since blood rheology began to be extensively studied in
hypertension, a main point was the possibility that hyper-
viscosity could be the link between high blood pressure
and organ damage, in particular cardiac involvement. In
hypertensive patients the cardiac left ventricle (LV) suffers
from a work overload consequent to the raised pressure in
aorta, so it develops a reactive increase in its muscular
mass. The degree of the LV hypertrophy is predictive of
cardiovascular morbidity and mortality (Levy et al.,
1990).
One of the earliest studies dealing with this issue was
published by Devereaux et al. in 1984 (Devereux et al.,
1984). Mean blood pressure was directly correlated to
blood viscosity in hypertensive and normotensive sub-
jects, although the correlation was statistically significant
only when the two groups were considered together. A
similar relation is a common but not constant finding in
studies about hypertension and hemorheology. In the
study performed by Devereaux et al., when the authors
plotted a graph of mean blood pressure against LV mass,
the relation was mildly significant in hypertensives. Sig-
nificantly stronger was the correlation between LV mass
and blood viscosity, and hypertensives without LV hyper-
trophy showed viscosity values overlapping those of the
normotensive controls. Even though this research pointed
out that in hypertensive subjects LV hypertrophy was bet-
ter related to blood viscosity than to mean blood pressure,
this did not demonstrate any causal relationship. The
authors hypothesized that hyperviscosity and LV hyper-
trophy could have vasoconstriction as a common cause.
Whatever the mechanism linking LV hypertrophy and
blood viscosity, the latter seemed to be a better indicator
of LV hypertrophy incidence than blood pressure itself.
Besides blood viscosity, also other rheological variables,
such as red cell aggregation or fibrinogen, were shown to
be related to LV mass (Zannad et al., 1988). A similar cor-
relation was observed about 20 years later by Fornal and
colleagues (Fornal et al., 2009) between LV mass and
erythrocyte deformability and aggregability. The study
group included 66 subjects with at least one cardiovas-
cular risk factor and without coronary heart disease. Forty-
nine of them (74%) were hypertensive, 20 were under
anti-hypertensive treatment. There was a correlation
between LV mass and rheological parameters. It is worth
noting that, in this very recent study, the techniques
employed to evaluate the LV mass and erythrocyte param-
eters are more accurate than those used in the previous
ones, but the results are confirmed. 
Leschke et al. (Leschke et al., 1990) studied 35 patients
with essential hypertension and ischemic heart pain
(angina pectoris), whose coronary arteries were not
obstructed by atherosclerotic plaques. All antihypertensive
medication had been withdrawn at least 48 hours before
measuring coronary reserve by dipyridamole test. The
control group included normotensive patients with atyp-
ical chest pain and normal coronary arteries, who under-
went coronary angiography and dipyridamole test to
exclude a macroscopic coronary disease and a coronary
microangiopathy. Hypertensives had significantly lower
coronary reserve and significantly higher hematocrit and
plasma viscosity. Fibrinogen and whole blood viscosity
were higher in hypertensives although not significantly.
When the hypertensive group was subdivided according to
the degree of coronary reserve impairment, only those
with a severe impairment showed significantly higher
hematocrit and plasma viscosity. The authors concluded
that blood rheology seemed to have a major role in deter-
mining coronary reserve impairment in hypertensives.
 
Blood rheology and antihypertensive drugs
Given the common hyperviscosity pattern associated
with hypertension, it was obvious to look for an effect of
the antihypertensive drugs on blood rheology. In partic-
ular, agents able to interfere with the sympathetic tone
such as beta-blockers, early emerged as perfect candi-
dates. Among the pioneering papers dealing with this
issue, it must be cited the article published by Dintenfass
in 1976 (Dintenfass and Lake, 1976), which described an
improved red cell deformability following therapy with
oxprenolol. Some years later, Caimi et al. (Caimi et al.,
1983) tested three beta blockers, observing a decrease in
blood viscosity only with timolol. No variation was
present in plasma viscosity, hematocrit or erythrocyte rhe-
ology with any of the drugs. 
A lot of antihypertensive drugs have been evaluated for
their possible influence on blood rheology. The list
includes, besides beta-blockers, calcium antagonists, ACE
inhibitors, diuretics, but the results as a whole have been
rather inconclusive. Some studies observed a hypovis-
cosemic effect, others no modifications, and even a dete-
rioration of the rheological pattern sometimes emerged. A
comprehensive survey is not feasible here (for a review
see Bogar, 2002 and Meiselman and Baskurt, 2006). 
Microrheological alterations in essential hyper-
tension
Over the last decades we have been investigating what
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can be defined the ‘microrheological pattern’, a rheolog-
ical property influencing circulation in microvessels,
where erythrocytes mainly flow as single cells and thus
their deformability plays a pivotal role.
The oldest studies about red cell deformability used to
evaluate it by filtering whole blood or suspensions of
washed erythrocytes. In the early 1990s we examined
erythrocyte filterability in hypertensive patients, employ-
ing the Reid and Dormandy method (Caimi et al., 1993)
and the Dodds and Dormandy method (unpublished
results). We observed a difference between controls and
hypertensives only by filtering whole-blood, and not by
filtering erythrocytes suspended in plasma. In the hyper-
tensive patients whole-blood filterability was lower, but
this method cannot rule out the influence of plasma pro-
teins or other circulating cells. We later studied red cell
deformability by diffractometry, under two different shear
stresses, in order to evaluate the intrinsic erythrocyte
deformability, and diffractometry was not able to dis-
criminate between hypertensives and controls (unpub-
lished data).
We subsequently employed fluorescence spectroscopy
techniques to explore red cell membrane dynamics in
hypertensives. This is a multi-faceted issue: on the one
hand, membrane fluidity is among the components of
erythrocyte deformability and among the factors influ-
encing oxygen delivery to tissues, both potential links
between hypertension and vascular ischemic diseases; on
the other hand, cell membrane fluidity is able to modulate
ion transport, signal transduction and other cell functions
whose alteration may be involved in the pathogenesis of
some forms of hypertension.
One of the fluorescence spectroscopy techniques
employed by us used fluorescent fatty acid derivatives:
the 2-(9-anthroyloxy)palmitic acid (2-AP) and three
stearic acid derivatives (6-AS, 9-AS, 12-AS). These mol-
ecules make it possible to evaluate the membrane flu-
idity at different depth from the lipid-water interface to
the hydrophobic core. We observed an increased fluo-
rescence polarization degree of all the fatty acid probes
embedded in the erythrocyte membrane (Caimi et al.,
1993), which was an index of reduced fluidity through-
out the phospholipid bilayer. A different fluorescence
spectroscopy technique employed pyrene derivatives.
The pyrene molecules tend to form complexes colliding
with each other, and the probability of collision is pro-
portional to the lateral mobility of the fluorescent probe.
Thus the intensity of pyrene complex fluorescence is an
index of how much the molecules carrying the fluo-
rescence probe are free to move within the membrane.
We used two probes, pyrene-decanoic acid (PDA), which
binds to phospholipids, and pyrene-3-maleimide (3-PM),
binding to proteins. We observed a reduced phospholipid
lateral mobility, while the protein lateral mobility was
not significantly altered (Caimi et al., 1997). Contem-
porary and more recent research by other authors
reported an impairment of erythrocyte membrane fluidity
in hypertension, employing either fluorescence methods
or electron paramagnetic resonance (Zicha et al., 1999;
Tsuda and Nishio, 2003). The latter was recently
employed to demonstrate that the antihypertensive drug
benidipine was able to improve the erythrocyte mem-
brane dynamics (Tsuda, 2008). The effect seemed to be
mediated by a raised level of nitric oxide (NO), which is
known to be produced by erythrocyte itself (Kleinbon-
gard et al., 2006) and to enhance erythrocyte deform-
ability (Bor-Kucukatay et al., 2003). Atomic force
microscopy recently showed an alteration of the mem-
brane skeleton structure in erythrocytes from patients
with essential hypertension, associated with an impaired
O2 membrane permeability (Kaczmarska et al., 2013).
The abnormalities of erythrocyte membrane dynamics
suggest an alteration of the membrane lipid pattern. We
examined this aspect and observed a significantly
decreased cholesterol/phospholipid ratio in hypertensives
(Caimi et al., 1993), but no significant variations of the sin-
gle phospholipid percentages using two-dimensional thin
layer chromatography (Caimi et al., 1991). Literature data
about cholesterol/phospholipid ratio and single phospho-
lipids are controversial in hypertension (Ronquist et al.,
1992; Fu et al., 1992). Rather than abnormalities in con-
centrations, some studies demonstrated an altered distri-
bution and transbilayer diffusion of cholesterol in the
erythrocyte membrane of hypertensive subjects (Muriana
et al., 1994; Muriana et al., 1995). Recently, there has been
some renewed interest in this topic. In 2012 Pytel and col-
leagues (Pytel et al., 2012) investigated the erythrocyte
membrane cholesterol level, finding no difference between
hypertensives and controls. They also explored the eryth-
rocyte membrane dynamics using diphenyl hexatriene
(DPH) and trimethylamino-phenyl-hexatriene (TMA-
DPH), which are fluorescent probes different from those
previously cited, and failed to detect abnormalities in
membrane fluidity. But in the same study the authors
examined some aspects of oxidative status in erythrocytes
of hypertensives, observing a higher lipid peroxidation
level and a lower activity of antioxidant enzymes. The
impairment of the red cell oxidative status suggests an
explanation for intrinsic erythrocyte membrane alterations
observed by us as well as by other authors in hypertension. 
But the red cell is not the only player in blood rheology.
If we extrapolate the erythrocyte role in microcirculation
we end up overlooking the whole picture. This prompted
investigation into other circulating cells’ behaviour in
hypertension. We performed some studies about leukocyte
rheology in hypertensive patients. We employed the St.
George filtrometer to filter leukocytes, as a whole and
subdivided into mononuclear and polymorphonuclear
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cells (Caimi et al., 1998). Only mononuclear cells showed
an impaired filterability, but it was difficult to make sense
of this result as they consist of a heterogeneous popu-
lation, including monocytes and all the lymphocyte sub-
sets. As regards the much more homogeneous population
of polymorphonuclear (PMN) leukocytes, the membrane
fluidity explored by the fluorescent probe TMA-DPH was
unaltered in resting cells, but a different behaviour
emerged, in comparison with normotensive controls, when
we activated PMNs in vitro with two agents: phorbol
myristate acetate (PMA) and N-formyl-methionyl-leucyl-
phenylalanine (fMLP). PMNs from hypertensive patients
in fact showed a significantly sharper drop in filterability
after activation, suggesting an abnormal functional state,
further supported by a high cytosolic Ca2+ basal concen-
tration (Caimi et al., 1998). 
These abnormalities of PMNs are part of the low-grade
inflammation recognized in arterial hypertension and
likely involved in the pathogenesis of its vascular com-
plications (Hopps et al., 2009; Harrison et al., 2011; Schif-
frin, 2013). 
Blood viscosity and endothelium
We measure the blood rheological properties in blood
freshly drawn from a large systemic vein. The blood
behaviour observed during in vitro measurements might
not be a reliable model of what happens in vivo, even if
we try to mime the flow conditions typical of different cir-
culatory districts employing a wide range of shear rates. A
major limitation of in vitro studies is the ruling out of
blood-endothelium interactions. It is known that endot-
helial cells are able to modulate vascular tone producing
various chemical agents, such as nitric oxide (NO), a gas
that diffuses to the underlying smooth muscular cells
inducing relaxation. One of the stimuli for NO release
from endothelium is the shear stress produced by blood
flow, and there is experimental evidence that an increase
in blood viscosity induced by hemoconcentration is fol-
lowed by a more effective endothelium-dependent vasodi-
lation (Intaglietta, 2008). So the character of harmful
factor traditionally attributed to blood hyperviscosity is
now questioned. 
Almost all the studies cited in this paper considered
hyperviscosity as a detrimental deviation from normality
and as a possible link between high blood pressure and
organ damage. But some doubts have been raised against
this statement (Forconi and Gori, 2009; Salazar Vásquez
et al., 2011). Hyperviscosity might share the destiny of
free radicals, traditionally considered dangerous byprod-
ucts of metabolism and more recently seen as mediators in
some physiological processes (Altenhöfer et al., 2012). In
a similar way, hyperviscosity may act as a homeostatic
factor in particular pathophysiological contexts. 
Conclusive considerations
Arterial hypertension is associated to hemorheological
abnormalities, which are evident at both macrorheological
and microrheological level. This is acquired knowledge,
but a question still open is what kind of relationship there
is exactly between arterial hypertension and hyperviscos-
ity. In fact, blood hyperviscosity may have a pathogenetic
role in the establishment of arterial hypertension, or may
be a further effect of the same pathogenetic processes
leading to hypertension. Moreover, blood hyperviscosity
may be a consequence of hypertension. This issue has
been properly defined a “chicken or egg” problem
(Meiselman, 1999; Bogar, 2002). 
Neither hyperviscosity itself nor its determinants have
ever gained credibility as faults to be corrected directly, by
drugs or otherwise, in hypertensive patients, should such
correction be possible. Though, taking into account blood
viscosity and its determinants is still relevant in research
about pathophysiology of human hypertension, as well as
in general circulation research, in order to outline a thor-
ough picture of the factors coming into play.
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